Guggenheim’s Rohit Vanjani is reassured from the sidelines on TEVA’s fremanezumab’s prospects to clear an FDA not despite supply plant’s Warning Letter.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced that it successfully priced the offering of $4.5 billion of its previously announced senior notes.
This analyst isn’t ready to get bullish on TEVA. Here’s why.
Warren Buffett is Betting Big on AAPL and TEVA.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares are climbing nearly 9% in Thursday’s trading session, after Warren Buffett’s Berkshire disclosed a $350 million brand …
Here’s a glimpse into this hedge fund guru’s Q2 moves that reeled back in three biotech players.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 …
Analyst says share weakness does not stem from encouraging news, but points to other underlying concerns.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Nuvelution Pharma are officially in collaboration for the development of AUSTEDO (deutetrabenazine) tablets, designed to treat Tourette …
Though Teva shares took a hit upon the news, the analyst sees an upside to expectations in the distance.
